Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q2FY22 Quarterly Result Announced for Suven Life Sciences Ltd.

 Highlights Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally. The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company. Clinical development pipeline: SUVN-502 (Masupirdine) – Completed phase 2 study on Alzheimer’s in USA and to be initiated phase 3 study on Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; expected completion by the year end 2024 SUVN-G3031 (Samelisant) – Ongoing phase 2 study on Narcolepsy in North America; expected completion by the year end 2022 SUVN-D4010 (Usmarapride) – Completed phase 1 study, ready for phase 2 SUVN-911 (Ropanicant) – Completed phase 1 study, ready for phase 2 Since last reporting period, the Company has been granted 13 patents for its innovative drug discovery covering ARIPO, China, Eurarisia, Hong Kong, Macao, South Africa, Sri Lanka, and USA. Result PDF
25-10-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Un-Audited Standalone And Consolidated Financial Results Under Ind AS For The Quarter And Half-Year Ended 30Th September, 2021.

 We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and half-year ended 30th September, 2021. b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and c) A copy of the News Release of our company Update on patents during this period can be viewed at: http://suven.com/Patentupdates.aspx We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:45 P.M.
25-10-2021
Bigul

Suven Life Sciences Ltd - 530239 - Statement Of Investor Complaints For The Quarter Ended September 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 018180 Name of the Signatory :- SHRENIK SONIDesignation :- Company Secretary and Compliance Officer
19-10-2021
Bigul

Suven Life Sciences Ltd - 530239 - Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results (Standalone And Consolidated) Of The Company Under Ind AS For The Half-Year Ended 30Th September, 2021 And Related Matters.

 SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2021 ,inter alia, to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the half-year ended 30th September, 2021 and related matters.
18-10-2021
Bigul

Suven Life Sciences Ltd - 530239 - Clarification On Price Movement

 With reference to above mentioned subject matter we write to inform that our company has been notifying NSE & BSE all the information which comes under the purview of Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time. At this point of time we do not have any material announcement/ event due for notification to the stock exchanges under Regulation 30 of SEBI LODR Regulations which may have a bearing on the price behavior of the scrip. The increase in the price of our security in the recent past appears to be based on market speculation and we have no other comment to offer on this development. We request you to disseminate this clarification on your website for information of general public, which is also being uploaded on our Company's website
11-10-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Shareholding for the Period Ended September 30, 2021

 Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here
06-10-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 This is to inform that the details of securities dematerialized/ rematerialized during the quarter ended September 30, 2021, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, have been furnished by KFin Technologies Private Limited, Registrar & Transfer Agent (RTA) of the Company to the stock exchanges where the shares of the Company are listed. Letters confirming this from KFin Technologies Private Limited dated October 05, 2021 are enclosed for your reference. This is for your information and record.
06-10-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 01st October, 2021 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter ending on 30th September, 2021, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. This is for your information and record.
30-09-2021
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from the following shareholders(s) regarding loss of share certificate(s). A copy of intimation letter enclosed herewith. Name of the Holder Folio No. No. of Shares Certificate No.(s) Distinctive Nos. date of receipt of information From To NISHA NARAYAN NERURKAR SPL004166 2000 12758 49513301 49515300 30/08/2021 2000 22758 107146551 107148550 The above said shareholder(s) of these shares have requested the company to send the procedure to obtain duplicate share certificate(s) in lieu of the original share certificate(s).
30-08-2021
Bigul

Suven Life Sciences' scrip gains 6.55%

 To initiate third phase of clinical trials
17-08-2021
Next Page
Close

Let's Open Free Demat Account